Maveropepimut-S
- Generic Name
- Maveropepimut-S
- Drug Type
- Biotech
- Background
Maveropepimut-S is a T cell activating immunotherapy.
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Target Recruit Count
- 102
- Registration Number
- NCT04920617
- Locations
- 🇺🇸
Boca Raton Regional Hospital, Boca Raton, Florida, United States
🇺🇸BRCR Medical Center Inc., Plantation, Florida, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 6
- Registration Number
- NCT04895761
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath